Synthesis and pharmacological evaluation of indole-based sigma receptor ligands

European Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2011, Pages 5154-5161

  Mésangeau, Christophe ^a   Amata, Emanuele ^a   Alsharif, Walid ^a   Seminerio, Michael J ^b   Robson, Matthew J ^b   Matsumoto, Rae R ^b   Poupaert, Jacques H ^c   McCurdy, Christopher R ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Indole; Sigma 2 receptors

Indexed keywords

1 (4 (4 CYCLOHEXYLPIPERAZIN 1 YL)BUTYL) 3 (4 FLUOROPHENYL) INDOLE DIOXALATE; 1 [4 (4 CYCLOHEXYL PIPERAZIN 1 YL) BUTYL] 3 FURAN 3 YLINDOLE DIOXALATE; 1 [4 (4 CYCLOHEXYL PIPERAZIN 1 YL) BUTYL] 3 PHENYLINDOLE DIOXALATE; 1 [4 [4 (4 FLUOROPHENYL) PIPERAZIN 1 YL] BUTYL] 3 FURAN 3 YLINDOLE DIOXALATE; 1 [4 [4(4 FLUOROPHENYL) PIPERAZIN 1 YL] BUTYL] 3 PHENYLINDOLE OXALATE; 2 (4 (3 (4 FLUOROPHENYL)INDOL 1 YL)BUTYL) 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE OXALATE; 2 (4 (3 (FURAN 3 YL)INDOL 1 YL)BUTYL) 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE OXALATE; 3 (4 (4 CYCLOHEXYLPIPERAZIN 1 YL)BUTYL)BENZO[D]THIAZOL 2(3H) ONE; 3 (4 FLUOROPHENYL) 1 (4 (4 (4 FLUOROPHENYL)PIPERAZIN 1 YL)BUTYL)INDOLE OXALATE; 6,7 DIMETHOXY 2 (4 (3 PHENYLINDOL 1 YL)BUTYL) 1,2,3,4 TETRAHYDROISOQUINOLINE OXALATE; ALPHA ADRENERGIC RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; INDOLE DERIVATIVE; PENTAZOCINE; SEROTONIN RECEPTOR; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MODULATION; NONHUMAN; PROTEIN BINDING; RADIOASSAY; RAT; RECEPTOR AFFINITY;

ANIMALS; CELL LINE; HUMANS; INDOLES; LIGANDS; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053206675     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.08.031     Document Type: Article

References (35)

1. R. Quirion, W.D. Bowen, Y. Itzhak, J.L. Jumien, J.M. Musacchio, R.B. Rothman, T.P. Su, S.W. Tam, and D.P. Taylor Trends Pharmacol. Exp. Ther. 13 1992 85 86
2. M. Hanner, F.F. Moebius, A. Flandorfer, H.G. Knaus, J. Striessnig, E. Kempner, and H. Glossmann Proc. Natl. Acad. Sci. U. S. A. 93 1996 8072 8077
3. P. Seth, Y.J. Fei, H.W. Li, W. Huang, F.H. Leibach, and V. Ganapathy J. Neurochem. 70 1998 922 931
4. R.R. Matsumoto Sigma receptors: historical perspective and background R.R. Matsumoto, W.D. Bowen, T.P. Su, Sigma Receptors: Chemistry, Cell Biology and Clinical Implications 2007 Springer New York 1 23
5. B. Bourrie, E. Bribes, J.M. Derocq, H. Vidal, and P. Casellas Curr. Opin. Invest. Drugs 5 2004 1158 1163
6. H.P. Volz, and K.D. Stoll Pharmacopsychiatry 37 2004 S214 S220
7. T. Maurice, and T.P. Su Pharmacol. Ther. 124 2009 195 206
8. C. Sanchez, J. Arnt, B. Costall, M.E. Kelly, E. Meier, R.J. Naylor, and J. Perregaard J. Pharmacol. Exp. Ther. 283 1997 1323 1332
9. V. Villard, J. Espallergues, E. Keller, T. Alkam, A. Nitta, K. Yamada, T. Nabeshima, A. Vamvakides, and T. Maurice Neuropsychopharmacology 34 2009 1552 1566
10. X. Guitart, X. Codony, and X. Monroy Psychopharmacology 174 2004 301 319
11. R.R. Matsumoto, Y. Liu, M. Lerner, E.W. Howard, and D.J. Brackett Eur. J. Pharmacol. 469 2003 1 12
12. T. Maurice, R. Martin-Fardon, P. Romieu, and R.R. Matsumoto Neurosci. Biobehav. Rev. 26 2002 499 527
13. S.R. Choi, B. Yang, K. Plossl, S. Chumpradit, S.P. Wey, P.D. Acton, K. Wheeler, R.H. Mach, and H.F. Kung Nucl. Med. Biol. 28 2001 657 666
14. B.J. Vilner, C.S. John, and W.D. Bowen Cancer Res. 55 1995 408 413
15. D.J. Rowland, Z. Tu, J. Xu, D. Ponde, R.H. Mach, and M.J. Welch J. Nucl. Med. 47 2006 1041 1048
16. Z. Tu, J. Xu, L.A. Jones, S. Li, C. Dumstorff, S. Vangveravong, D.L. Chen, K.T. Wheeler, M.J. Welch, and R.H. Mach J. Med. Chem. 50 2007 3194 3204
17. R.H. Mach, C.R. Smith, I. al-Nabulsi, B.R. Whirett, S.R. Childers, and K.T. Wheeler Cancer Res. 57 1997 156 161
18. M.S. Ostenfeld, N. Fehrenbacher, M. Hoyer-Hansen, C. Thomsen, T. Farkas, and M. Jaattela Cancer Res. 65 2005 8975 8983
19. K.W. Crawford, and W.D. Bowen Cancer Res. 62 2002 313 322
20. S. Narayanan, R. Bhat, C. Mesangeau, J.H. Poupaert, and C.R. McCurdy Future Med. Chem. 3 2011 79 94
21. D.Y. Maeda, W. Williams, W.D. Bowen, and A. Coop Bioorg. Med. Chem. Lett. 10 2000 17 18
22. C.A. Maier, and B. Wunsch J. Med. Chem. 45 2002 4923 4930
23. S. Yous, W. Wallez, M. Belloir, D.H. Caignard, C.R. McCurdy, and J.H. Poupaert Med. Chem. Res. 14 2005 158 168
24. A.C. Gassiot, J. Charton, S. Girault-Mizi, P. Gilleron, M.A. Debreu-Fontaine, C. Sergheraert, and P. Melnyk Bioorg. Med. Chem. Lett. 15 2005 4828 4832
25. A.R. Hajipour, D. Fontanilla, U.B. Chu, M. Arbabian, and A.E. Ruoho Bioorg. Med. Chem. 18 2010 4397 4404
26. J. Perregaard, E.K. Moltzen, E. Meier, and C. Sanchez J. Med. Chem. 38 1995 1998 2008
27. R.H. Mach, Y. Huang, R.A. Freeman, L. Wu, S. Vangveravong, and R.R. Luedtke Bioorg. Med. Chem. Lett. 14 2004 195 202
28. C. Mesangeau, S. Narayanan, A.M. Green, J. Shaikh, N. Kaushal, E. Viard, Y.T. Xu, J.A. Fishback, J.H. Poupaert, R.R. Matsumoto, and C.R. McCurdy J. Med. Chem. 51 2008 1482 1486
29. Standard conditions for Suzuki were followed; see for example U. Jacquemard, S. Routier, N. Dias, A. Lansiaux, J.F. Goossens, C. Bailly, and J.Y. Merour Eur. J. Med. Chem. 40 2005 1087 1095
30. E.C. Nguyen, K.A. McCracken, Y. Liu, B. Pouw, and R.R. Matsumoto Neuropharmacology 49 2005 638 645
31. R.R. Matsumoto, W.D. Bowen, M.A. Tom, V.N. Vo, D.D. Truong, and B.R. De Costa Eur. J. Pharmacol. 280 1995 301 310
32. R.R. Matsumoto, J. Shaikh, L.L. Wilson, S. Vedam, and A. Coop Eur. Neuropsychopharmacol. 18 2008 871 881
33. R.R. Matsumoto, and B. Pouw Eur. J. Pharmacol. 401 2000 155 160
34. J.A. Fishback, C. Mesangeau, J.H. Poupaert, C.R. McCurdy, and R.R. Matsumoto Eur. J. Pharmacol. 653 2011 1 7
35. Y. Cheng, and W.H. Prusoff Biochem. Pharmacol. 22 1973 3099 3108